secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2026-09-10T12:16:11+00:00
Accession:  0001193125-26-387310
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics appoints Martine Zimmermann to board; BLA submission planned Q4 2026
--------------------------------------------------------------------------------

- Board expanded from 10 to 11 directors; Zimmermann appointed effective Sept 8, 2026, as Class III director with term to 2027 annual meeting.
- Compensation: option for 64,000 shares vesting monthly over 3 years; $40,000 annual retainer paid quarterly.
- Zimmermann brings 30+ years regulatory/quality experience; currently EVP at Inventiva, previously SVP at Ipsen and Alexion.
- Company reiterates planned BLA submission for aglatimagene besadenovec in Q4 2026; appointment supports commercial readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/0001193125-26-387310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-20260906.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-387310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer